awmsg logo



glecaprevir/pibrentasvir (Maviret®)


Reference No. 3917

Publication date:
25/10/2019


Appraisal information

glecaprevir/pibrentasvir (Maviret®) 100 mg/40 mg film-coated tablet


Company: AbbVie Ltd
BNF category: Infections
NMG meeting date: 04/09/2019
AWMSG meeting date: 16/10/2019
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1319
Ratification by Welsh Government: 22/10/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Glecaprevir/pibrentasvir (Maviret®) is recommended as an option for use within NHS Wales for the treatment of chronic hepatitis C virus (HCV) infection in adolescents aged 12 to < 18 years. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download